Intelligent Pain Management System with Preservative-Free Intranasal Composition

Publication ID: 24-11857520_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Pain Management System with Preservative-Free Intranasal Composition,” Published Technical Disclosure No. 24-11857520_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857520_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,520.

Summary of the Inventive Concept

The invention integrates a preservative-free intranasal composition with advanced technologies such as AI, IoT, and blockchain to create a personalized, data-driven pain management system for treating various pain conditions.

Background and Problem Solved

The original patent disclosed a preservative-free intranasal composition for treating pain associated with tri-geminal neuralgia, facial neuropathic pain, facial cancer induced neuropathic pain, migraine pain, and cluster headache pain. However, the original composition lacked real-time monitoring and personalized dosing capabilities, which limited its effectiveness. The new inventive concept addresses these limitations by incorporating advanced technologies to provide a more efficient and effective pain management system.

Detailed Description of the Inventive Concept

The system consists of a preservative-free intranasal composition dispenser, an AI-powered pain monitoring system, and a communication module for transmitting patient data to a healthcare provider. The dispenser is actuated by a mechanical pump metered dose spray device and is integrated with a wearable IoT device that provides real-time feedback on optimal dosing and administration techniques. The system utilizes a blockchain-based tracking mechanism to monitor patient adherence to the pain treatment regimen. The AI-powered pain monitoring system analyzes data from the wearable IoT device and identifies optimal dosing regimens and administration techniques, transmitting the optimized treatment plan to a healthcare provider via a blockchain-based communication network.

Novelty and Inventive Step

The new claims introduce the integration of advanced technologies such as AI, IoT, and blockchain with the preservative-free intranasal composition, providing a novel and non-obvious solution for personalized pain management. The inventive step lies in the synergistic combination of these technologies to create a more efficient and effective pain management system.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include integrating the preservative-free intranasal composition with other advanced technologies such as virtual or augmented reality, or using different types of dispensers or administration devices. Variations of the system could include using different AI algorithms or blockchain platforms, or incorporating additional sensors or monitoring systems.

Potential Commercial Applications and Market

The intelligent pain management system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of chronic pain conditions. The system's ability to provide personalized, data-driven pain management solutions could lead to improved patient outcomes and reduced healthcare costs.

CPC Classifications

Section	Class	Group
A	A61	A61K31/167
A	A61	A61K9/0043
A	A61	A61M11/00
A	A61	A61M2210/0618

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Medical Device Technologies, Pharmaceutical Formulations, Pain Management Systems, with expertise in intranasal drug delivery, medical device design, and digital health technologies

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or medical technology, possessing knowledge of drug delivery systems, digital health platforms, and pain management technologies

Obviousness Rationale

A PHOSITA would recognize that integrating digital monitoring technologies with existing preservative-free intranasal pain management compositions represents a predictable technological evolution. The source patent's intranasal lidocaine composition provides a clear foundation for exploring enhanced delivery and monitoring mechanisms. The proposed technological integrations (AI, IoT, blockchain) represent standard approaches to improving medical treatment tracking and personalization that would be obvious to implement with existing pharmaceutical formulations.

Obvious Combinations & Variations

Source Patent Element

Preservative-free intranasal lidocaine composition for pain management

PTD Variation

Adding AI-powered dosage optimization and IoT monitoring to the intranasal delivery system

Obviousness Reasoning

Integrating digital monitoring with pharmaceutical delivery is a known technique in medical technology, representing a predictable application of existing digital health platforms to established drug delivery methods

Source Patent Element

Mechanical multi-dose nasal spray pump device

PTD Variation

Incorporating blockchain-based patient adherence tracking with the existing spray mechanism

Obviousness Reasoning

Tracking patient medication usage through digital platforms is a standard approach in medical technology, representing an obvious extension of existing device functionality

Source Patent Element

Lidocaine-based pain treatment for specific neurological conditions

PTD Variation

Creating a personalized treatment system using patient-specific data and AI algorithms

Obviousness Reasoning

Customizing medical treatments using patient data and predictive algorithms is a well-established approach in precision medicine, representing a logical and obvious technological progression

Source Patent Element

Unit-dose nasal spray formulation

PTD Variation

Implementing real-time dosage feedback through integrated IoT sensors

Obviousness Reasoning

Enhancing medication delivery with real-time monitoring is a predictable technological improvement that would be obvious to a skilled practitioner in medical device design

Source Patent Element

Intranasal pain management composition

PTD Variation

Adding wearable device integration for continuous pain monitoring

Obviousness Reasoning

Extending pharmaceutical treatments with continuous monitoring technologies represents a standard approach in digital health innovation, with predictable and expected results

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857520 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed integrations of preservative-free intranasal compositions with digital health technologies to be obvious and non-inventive. The combination of known pharmaceutical formulations with standard digital monitoring approaches does not represent a non-obvious technological advancement, thereby rendering potential claims in this domain anticipated and obvious under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,857,520
Title	Therapeutic composition of intranasal lidocaine
Assignee(s)	Nortic Holdings Inc.